Sorafenib plus Doxorubicin versus Sorafenib alone for advanced hepatocellular carcinoma (SORADOX trial): interim results of a prospective, randomized, open-label, multicenter phas…
TJ Ettrich, S Behl, AW Berger, A Zipprich, DT Waldschmidt, MA Wörns, S Belle, P Michl, T Seufferlein, MM Dollinger · Zeitschrift für Gastroenterologie · 2014 · Heft 08
Bibliografische Angaben
Zusammenfassung
Introduction: Sorafenib is currently regarded as standard of care in patients with hepatocellular carcinoma BCLC stage C. Recent results of a Phase II study with Doxorubicin +/- Sorafenib investigating time to progression (TTP) and overall survival (OS) demonstrated an increased OS of 3 months in the combination arm as compared with Sorafenib alone in the original Sharp trial. Aim: To assess efficacy and safety of the combination therapy Sorafenib plus Doxorubicin against standard-of-care Sorafenib alone in advanced HCC not amenable to non-systemic treatment. Methods: A prospective, randomized, open-label, multi…
